Twenty-six attorneys general on both sides of the aisle called on Medicare on Monday to cover antibody-based Alzheimer’s treatments like Eisai and Biogen’s Leqembi (lecanemab) without restrictions and to reverse a controversial policy that limits coverage to patients in clinical trials.
Gentner Drummond
The letter, led…
